Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Bassia Scoparia Pollen is an allergenic extract used for the diagnosis and treatment of seasonal allergic rhinitis and conjunctivitis. It belongs to the class of non-standardized pollen allergenic extracts used in immunotherapy.
Name
Bassia Scoparia Pollen
Raw Name
BASSIA SCOPARIA POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
16
Variant Count
17
Last Verified
February 17, 2026
About Bassia Scoparia Pollen
Bassia Scoparia Pollen is an allergenic extract used for the diagnosis and treatment of seasonal allergic rhinitis and conjunctivitis. It belongs to the class of non-standardized pollen allergenic extracts used in immunotherapy.
Detailed information about Bassia Scoparia Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Bassia Scoparia Pollen.
Bassia Scoparia Pollen, derived from the plant Bassia scoparia (formerly known as Kochia scoparia), is a potent aeroallergen utilized in clinical immunology for both diagnostic and therapeutic purposes. Known commonly as Burning Bush, Summer Cypress, or Mexican Fireweed, this plant is a member of the Amaranthaceae family and is a prolific producer of wind-borne pollen, particularly in arid and semi-arid regions of North America, Eurasia, and Australia. In the context of clinical pharmacology, Bassia Scoparia Pollen belongs to a class of drugs called Non-Standardized Pollen Allergenic Extracts [EPC].
These extracts are biological products regulated by the FDA's Center for Biologics Evaluation and Research (CBER). Unlike standardized extracts (such as those for short ragweed or grass), non-standardized extracts like Bassia Scoparia are measured in units of weight/volume (w/v) or Protein Nitrogen Units (PNU) rather than bioequivalent allergy units (BAU). The primary clinical utility of this extract is in the management of Type I hypersensitivity reactions (IgE-mediated) that manifest as allergic rhinitis (hay fever), allergic conjunctivitis, and allergic asthma.
The mechanism of action for Bassia Scoparia Pollen extract varies depending on its application. In diagnostic skin testing, the extract is introduced into the epidermis or dermis. If the patient has pre-existing IgE antibodies specific to Bassia scoparia proteins, these antibodies—which are bound to the surface of mast cells—will cross-link upon contact with the allergen. This triggers mast cell degranulation, releasing inflammatory mediators such as histamine, leukotrienes, and prostaglandins, resulting in a characteristic 'wheal and flare' reaction within 15 to 20 minutes.
When used for Allergen Immunotherapy (AIT), often referred to as 'allergy shots,' the mechanism is more complex and involves the induction of peripheral immune tolerance. According to clinical guidelines from the American Academy of Allergy, Asthma & Immunology (AAAAI), repeated subcutaneous administration of increasing doses of the allergen shifts the immune response from a Th2-dominated profile (which promotes IgE production) to a Th1 or T-regulatory (Treg) cell response. This leads to the production of 'blocking antibodies' (IgG4 and IgA), which compete with IgE for allergen binding, and the secretion of anti-inflammatory cytokines like Interleukin-10 (IL-10) and Transforming Growth Factor-beta (TGF-β).
Traditional pharmacokinetic studies (Absorption, Distribution, Metabolism, and Excretion) are generally not applicable to allergenic extracts in the same way they are for small-molecule drugs. However, the following principles apply to their clinical use:
Bassia Scoparia Pollen extracts are FDA-approved for the following indications:
Off-label uses may include specialized research protocols for studying the cross-reactivity between Bassia scoparia and other Chenopodiaceae/Amaranthaceae pollens, such as Chenopodium album (Lamb's quarters).
Bassia Scoparia Pollen is typically available in the following formulations:
> Important: Only your healthcare provider can determine if Bassia Scoparia Pollen is right for your specific condition. Immunotherapy should only be administered under the supervision of a physician prepared to treat systemic anaphylaxis.
Dosage for Bassia Scoparia Pollen allergenic extract is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity level and clinical response. There is no standard 'one-size-fits-all' dose.
Immunotherapy follows a two-phase schedule:
Bassia Scoparia Pollen extract is generally considered safe for use in children, typically starting around age 5. Dosing follows the same weight/volume or PNU escalation protocols used in adults, though clinicians may exercise greater caution in the initial build-up phase. The decision to start immunotherapy in very young children (under age 5) is made on a case-by-case basis, as they may have difficulty communicating the early symptoms of a systemic reaction.
No specific dosage adjustments are typically required for patients with renal or hepatic impairment, as the systemic load of the allergenic protein is minimal. However, the patient's overall health and ability to tolerate a potential systemic reaction must be considered.
Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk of using epinephrine (the treatment for anaphylaxis) in patients with heart disease must be weighed against the benefits of immunotherapy.
During the peak pollination season for Bassia scoparia (typically late summer to autumn), the maintenance dose may be reduced by 50% or more to prevent an 'overload' of allergen exposure, which increases the risk of systemic reactions.
If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on the length of the delay. If a maintenance dose is missed by more than a week, the physician may reduce the dose for the next injection to ensure safety. Never attempt to 'double up' on doses.
An 'overdose' in the context of allergenic extracts refers to the administration of a dose higher than the patient's current tolerance level. This can lead to severe systemic reactions or anaphylaxis. Symptoms include generalized hives, swelling of the throat, wheezing, and a drop in blood pressure. Emergency treatment with epinephrine is required immediately.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most patients undergoing immunotherapy with Bassia Scoparia Pollen will experience local reactions. These are generally not dangerous but can be uncomfortable.
These reactions are systemic but usually mild to moderate in severity:
> Warning: Stop taking Bassia Scoparia Pollen and call your doctor immediately if you experience any of these.
There are no known long-term 'toxic' effects of Bassia Scoparia Pollen extracts, as they are composed of natural proteins. However, the primary long-term risk is the development of new sensitivities or the persistence of local skin changes (granulomas) at injection sites if the same location is used repeatedly over many years. Some patients may experience a 'rebound' of symptoms if immunotherapy is discontinued prematurely.
While specific 'Black Box' warnings are often associated with sublingual immunotherapy (SLIT) tablets, all injectable allergenic extracts carry a heavy warning regarding the risk of Anaphylaxis. The FDA-approved labeling for allergenic extracts emphasizes that these products should only be administered in a setting where emergency equipment and trained personnel are available to treat life-threatening systemic reactions. Patients with unstable asthma are at the highest risk for fatal outcomes following an injection.
Report any unusual symptoms to your healthcare provider.
Bassia Scoparia Pollen extract is a biological product that can induce severe allergic reactions. It is intended for use only by physicians experienced in the diagnosis and treatment of allergic diseases. Patients must be informed of the risks and benefits before beginning a course of immunotherapy.
No specific FDA black box warning exists for the Bassia scoparia extract itself, but the class of injectable allergenic extracts carries a general mandate for administration only in specialized clinical settings. The labeling for similar products (like SLIT) often includes a black box warning for anaphylaxis, and the same clinical caution applies here. Fatalities have occurred with allergenic extracts when administered to patients with uncontrolled asthma or when dosing errors occurred.
Generally, Bassia Scoparia Pollen does not affect the ability to drive. However, if a patient experiences a systemic reaction, dizziness, or takes an antihistamine to treat a local reaction, their ability to operate machinery may be impaired.
Alcohol should be avoided for several hours before and after an injection. Alcohol can increase blood flow to the skin (vasodilation), which may speed up the absorption of the allergen and increase the risk of a systemic reaction.
If immunotherapy is discontinued, it should be done under a doctor's guidance. Stopping suddenly does not cause withdrawal, but the patient's allergy symptoms will likely return to their baseline levels over time.
> Important: Discuss all your medical conditions with your healthcare provider before starting Bassia Scoparia Pollen.
For each major interaction, the management strategy usually involves either switching the interacting medication (e.g., moving from a beta-blocker to a calcium channel blocker) or delaying the immunotherapy until the patient's medication regimen is stabilized.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Patients allergic to Bassia Scoparia Pollen often show cross-sensitivity to other members of the Amaranthaceae and Chenopodiaceae families. This includes:
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Bassia Scoparia Pollen.
FDA Pregnancy Category C. There are no adequate and well-controlled studies of Bassia Scoparia Pollen extract in pregnant women. The general clinical consensus is:
It is generally considered safe to continue Bassia Scoparia Pollen immunotherapy while breastfeeding. The allergenic proteins are not expected to pass into breast milk in significant quantities, and there is no evidence of harm to the nursing infant. However, the mother should be monitored for systemic reactions as usual.
Immunotherapy is approved for use in children. Clinical trials have shown that it can be effective in reducing the progression from allergic rhinitis to asthma (the 'allergic march'). Special care is taken to ensure the child can sit still for the injection and remain for the 30-minute observation period. Dosing is based on clinical sensitivity rather than body weight.
In patients over 65, the primary concern is the presence of comorbid conditions like coronary artery disease or COPD. The physician must determine if the patient's heart can handle the stress of a systemic reaction or the administration of epinephrine. Renal clearance of the degraded proteins is generally not a concern in this population.
No specific dose adjustments are required. The proteins in the extract are broken down into amino acids and small peptides, which do not pose a significant burden on the kidneys.
No specific dose adjustments are required. Liver function does not significantly impact the processing of subcutaneous allergenic extracts.
> Important: Special populations require individualized medical assessment.
Bassia Scoparia Pollen extract contains several major and minor allergens, including profilins and polcalcins. At the molecular level, immunotherapy works by:
The onset of action for diagnostic skin testing is rapid (15–20 minutes). For immunotherapy, the onset of clinical benefit is slow, usually taking 3–6 months to notice a reduction in symptoms and 12–18 months for peak effect. The duration of the effect can last for several years after a 3–5 year course of treatment is completed.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous/Local) |
| Protein Binding | Minimal systemic binding |
| Half-life | Proteins degraded within hours |
| Tmax | 15-30 minutes (local) |
| Metabolism | Proteolytic cleavage |
| Excretion | Renal (metabolites) |
Classified as a Non-Standardized Pollen Allergenic Extract. It is grouped with other weed pollens like Ragweed, Sagebrush, and Pigweed extracts.
Common questions about Bassia Scoparia Pollen
Bassia Scoparia Pollen extract is primarily used for the diagnosis and treatment of seasonal allergies caused by the Burning Bush or Summer Cypress plant. In diagnosis, it is used in skin prick tests to identify if a patient is allergic to this specific weed. In treatment, it is used in allergen immunotherapy, also known as allergy shots, to help desensitize the immune system over time. This can significantly reduce symptoms like sneezing, itchy eyes, and nasal congestion. It is typically reserved for patients who do not get enough relief from standard over-the-counter allergy medications.
The most common side effects are local reactions at the site of the injection, occurring in nearly all patients at some point. These include redness, itching, and swelling that can range from the size of a dime to the size of a half-dollar. Some patients may also experience a 'late-phase' reaction where the area becomes hard and warm several hours later. Systemic side effects like hives or a runny nose are less common but can occur. Because of the risk of a severe reaction called anaphylaxis, patients must always be monitored for 30 minutes after receiving the extract.
It is strongly recommended to avoid alcohol on the days you receive your Bassia Scoparia Pollen injections. Alcohol causes vasodilation, which is the widening of blood vessels, and this can increase the speed at which the allergen is absorbed into your bloodstream. Faster absorption increases the risk of a systemic allergic reaction or anaphylaxis. Additionally, alcohol can mask the early symptoms of a reaction, making it harder for you or your doctor to identify a problem. Always wait at least several hours after your injection before consuming any alcoholic beverages.
Bassia Scoparia Pollen immunotherapy is generally not started during pregnancy because of the risk of a severe allergic reaction, which could deprive the fetus of oxygen. However, if you are already on a stable maintenance dose and become pregnant, your allergist may recommend continuing the treatment since the risk of a reaction is much lower at that stage. There is no evidence that the pollen extract itself causes birth defects. You should have a detailed discussion with your allergist and obstetrician to weigh the risks and benefits. Most doctors will not increase your dose while you are pregnant.
Allergen immunotherapy is a long-term treatment and does not provide immediate relief like an antihistamine. Most patients begin to notice an improvement in their allergy symptoms toward the end of the 'build-up' phase, which usually takes 3 to 6 months. Significant relief is typically achieved after one full year of maintenance injections. For the best and most lasting results, a full course of treatment usually lasts between 3 and 5 years. If no improvement is seen after 12 to 18 months, your doctor may re-evaluate the treatment plan.
Yes, you can stop taking Bassia Scoparia Pollen injections suddenly without experiencing physical withdrawal symptoms like you might with some other medications. However, stopping treatment prematurely, especially before the 3-to-5-year mark, often results in the return of your original allergy symptoms. The immune system may 'forget' the tolerance it was building, and you may find yourself needing daily medications again. It is always best to discuss your reasons for wanting to stop with your allergist. They can help you decide if a different schedule or a different treatment might be better for you.
If you miss a dose of Bassia Scoparia Pollen, you should contact your allergist's office as soon as possible to reschedule. Do not try to make up for the missed dose by taking more the next time. Depending on how long it has been since your last injection, your doctor may need to reduce the dose for your next visit to ensure your safety. If you miss several weeks during the build-up phase, you might even need to restart at a lower concentration. Consistency is key to both the safety and the effectiveness of allergy immunotherapy.
There is no clinical evidence to suggest that Bassia Scoparia Pollen allergenic extracts cause weight gain. The extract consists of natural proteins and is administered in very small amounts that do not affect your metabolism or appetite. If you experience weight gain while undergoing immunotherapy, it is likely due to other factors, such as the use of oral corticosteroids for asthma or changes in diet and exercise. If you are concerned about weight changes, discuss them with your primary care physician to identify the underlying cause.
Bassia Scoparia Pollen can be taken with many other medications, but some interactions are very serious. You must tell your doctor if you are taking beta-blockers, ACE inhibitors, or MAO inhibitors, as these can make allergic reactions more dangerous or harder to treat. Antihistamines and certain antidepressants can also interfere with the results of skin testing. Most common medications for blood pressure, cholesterol, and diabetes do not interact with allergy shots. Always provide your allergist with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you use.
The concept of 'generic' vs. 'brand name' is different for allergenic extracts than for pills. Bassia Scoparia Pollen extracts are biological products produced by several different laboratories (such as ALK, Greer, or HollisterStier). While they all contain the same pollen proteins, they are not considered interchangeable in the same way generic drugs are. If your doctor switches you from one manufacturer's extract to another, they will often restart the build-up process or reduce the dose to be safe. Always ensure your injections are coming from a consistent and reliable source.